Concepedia

Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases

Ammoren Dohm, Justyn Y. Nakashima, Hruday Kalagotla, Shirley Jiang, Joseph D. Tang, Menal Bhandari, Youngchul Kim, Jasmine A. Graham, Nikhil I. Khushalani, Peter Forsyth,

European Journal of Cancer · 2023 · 33 citations · 18 references

DOIFull text

Open access

Concepts

References

18

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

F. Stephen Hodi, Vanna Chiarion‐Sileni, René González et al. · The Lancet Oncology · 2018 · 1.4K citations

, , +16

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Georgina V. Long, Victoria Atkinson, Serigne Lo et al. · The Lancet Oncology · 2018 · 996 citations

, , +13

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Michael A. Davies, Philippe Saïag, Caroline Robert et al. · The Lancet Oncology · 2017 · 775 citations · Full text

, , +12

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

The Lancet Oncology · 2021 · 322 citations · Full text

, , +16

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation

Allison Martin, Daniel Cagney, Paul J. Catalano et al. · JAMA Oncology · 2018 · 307 citations · Full text

, , +17